Skip to main content
Clinical Trials/KCT0003227
KCT0003227
Completed
N/A

A pilot clinical trial to evaluate the efficacy and safety of R:GEN(Selective retina therapy) which induce to reduce drusen in patients with intermediate dry Age-related Macular Degeneration

Overview

Phase
N/A
Intervention
Not specified
Conditions
Diseases of the eye and adnexa
Sponsor
The Catholic University of Korea, Yeouido St. Mary's Hospital
Enrollment
20
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • (1\) age greater than 50 years;
  • (2\) bilateral intermediate AMD corresponding to Age\-related eye disease study (AREDS) Category 3 (multiple drusen with at least one druse \=125 µm;
  • (3\) best corrected visual acuity (BCVA) of 20/63 or better according to the Early Treatment Diabetic Retinopathy Study (ETDRS) using the logarithm of the minimum angle of resolution (logMAR) chart;

Exclusion Criteria

  • any presence of choroidal neovascularization (CNV); serous pigment epithelium detachment (PED) on color fundus photography (CFP) and OCT; the presence of any hypofluorescent lesion on fundus autofluorescence (FAF) consistent with geographic atrophy (GA); patients who had undergone intraocular surgery (such as cataract surgery or vitrectomy); and patients who were unable to be treated with laser due to the presence of a cataract or vitreous opacity. Eligibility for the study was determined by three retina specialists based on CFP and OCT findings. FFA was performed to confirm the absence of choroidal neovascularization (CNV) in cases where wet AMD was suspected.

Outcomes

Primary Outcomes

Not specified

Similar Trials